image
Inhibikase Therapeutics, Inc. IKT
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 2.05
-13.1 %
$ 138 M
Market Cap
-0.64
P/E
FREE CASH FLOW TO FIRM (OWNERS EARNINGS)
DCF Model Base Case Scenario
Cash Flow For Owners Growth Estimate the growth of (owners) cash flows per year for the next 10 years.
%
Maintenance CAPEX Estimate the percentage of CAPEX that is needed for maintenance.
%
Required Rate Of Return The required rate of return is a personal target return, before considering a margin of safety.
%
Terminal Growth Rate Terminal Value reflects the expected growth of cash flows after the 10th year and into perpetuity.
%

Owners Calculation

Millions
Current Year Forecasted Year 1 Forecasted Year 2 Forecasted Year 3 Forecasted Year 4 Forecasted Year 5 Forecasted Year 6 Forecasted Year 7 Forecasted Year 8 Forecasted Year 9 Terminal
Operating Cash Flow (18.1)
CAPEX 14.2 K
Maintenance CAPEX 9.97 K
Cash Flow For Owners (18.1) (83.3) (383.7) (1 767.0) (8 137.1) (37 471.3) (172 554.9) (794 612.5) (3 659 177.4) (16 850 451.5) (1 455 594 895.7)
Cash and Cash Equivalents The current cash and cash equivalents of the company.
M
Total Debt The current total debt of the company.
M
Fair Value The calculated fair value of the company.
$
Valuation The valuation against current price.
%